Introduction
============

Dental caries is the most common chronic disease of childhood and its prevalence continues to increase in many populations worldwide.[@b1-ccide-7-107],[@b2-ccide-7-107] It is a multifactorial disease mainly caused by interactions between mutans streptococci, especially *Streptococcus mutans* and *Streptococcus sobrinus*, and individual caries risk factors, such as saliva composition, fluoride exposure, and dietary habits.[@b3-ccide-7-107] Despite dental caries being preventable and the many major technological advances in dentistry in recent years,[@b4-ccide-7-107] dental caries remains a very diffuse and unsolved medical problem. Being a pathology sustained by microbial pathogens, treatments using conventional antistreptococcal antibiotics can be effective in the short term to reduce dental plaque levels and to decrease counts of the mutans streptococci. However, as most antibiotics have relatively broad-spectrum antimicrobial activity, they indiscriminately destroy both commensal and potentially harmful bacteria and thereby create population imbalances within the microflora.[@b5-ccide-7-107] This outcome could be a consequence of using well-known natural or synthetic antibiotics and also of using new herbal medicines endowed with antibiotic activity.[@b6-ccide-7-107],[@b7-ccide-7-107] It is now becoming clear that the severity of some oral pathologies, including dental caries, otitis media, halitosis, and streptococcal pharyngotonsillitis, can be related to the development of oral microbiota disequilibria. The application of oral probiotics to help restore a balanced microbiota and thereby improve oral health is a relatively new concept.[@b8-ccide-7-107] Some putative commensal bacteria have been assessed for their ability to help prevent dental caries. Some initial studies based on the use of intestinal probiotics have reported a reduction in levels of *S. mutans* and apparently fewer dental caries.[@b9-ccide-7-107],[@b10-ccide-7-107] However, because these strains have limitations in terms of their colonization of oral tissues, a new generation of probiotic strains sourced from the human oral cavity and belonging to commensal species known to have extremely low pathogenic potential has more recently been developed. In this regard, a key species is *Streptococcus salivarius* and the oral probiotic identified as strain K12 has been the most thoroughly studied in terms of its bacteriocin production, oral colonization, and oral persistence and also its efficacy in counteracting halitosis, oral candidosis, pharyngotonsillitis, and acute otitis media.[@b11-ccide-7-107]--[@b22-ccide-7-107] *Streptococcus salivarius* M18 (*salivarius* M18) (IDA classification: DSM 14865),[@b23-ccide-7-107] a strain originally isolated from a healthy female adult subject during a specific search for an oral commensal strain capable of inhibiting mutans streptococci, has subsequently been shown to have relatively broad spectrum bacteriocin-like inhibitory substance (BLIS) activity against *S. mutans* and *S. sobrinus* and to produce both dextranase and urease enzymes, the activities of which could potentially help limit the progression of dental caries by reducing plaque accumulation and plaque acidification, respectively.[@b24-ccide-7-107]--[@b26-ccide-7-107] The whole genome of strain *salivarius* M18 has been published recently, and its bacteriocin repertoire includes the megaplasmid-encoded salivaricin A~2~, salivaricin MPS, and salivaricin 9, and the chromosomally encoded salivaricin M.[@b23-ccide-7-107],[@b24-ccide-7-107],[@b27-ccide-7-107] Recent trials have revealed, along with its safety and tolerability profiles, the capability of *salivarius* M18 to colonize and persist in the human oral cavity,[@b28-ccide-7-107] to reduce plaque formation and to lower *S. mutans* counts in colonized primary-school-aged children,[@b29-ccide-7-107] and to reduce both moderate and severe gingivitis and periodontitis in adults.[@b30-ccide-7-107] On the basis of these biochemical, microbiological, and clinical findings, we determine whether the oral and daily use of the strain *salivarius* M18 affects or modifies the Cariogram outcome after 90 days of treatment in children at high risk of developing new dental caries. Cariogram is an algorithm-based software program developed in Sweden in 1997 by the University of Malmö, based on nine different caries-related risk factors, along with physician judgment, intended to aid clinicians in performing more objective and consistent dental caries risk assessments.[@b31-ccide-7-107] The performance of the program has been validated in preschool children, schoolchildren, young adults, and the elderly.[@b32-ccide-7-107]--[@b38-ccide-7-107]

Materials and methods
=====================

Subjects and criteria
---------------------

Seventy-six children (aged 6--17 years) classified as high risk on the basis of the Cariogram results performed at day 0 (chance to avoid new cavities \<25) were included in this randomized, controlled study after informed consent was obtained from their parents. Exclusion criteria were diagnosis of heart, respiratory, renal, liver, or intestinal disease, or undergoing current therapy with antibiotics and/or corticosteroids for the prevention/treatment of recurrent bacterial pathologies, such as cystitis, pharyngotonsillitis, and acute otitis media, or to counteract allergic reactions and/or asthma. According to the protocol, occasional use of acetaminophen or ibuprofen for fever and/or pain control and of physician-prescribed antibiotics was allowed. During the use of antibiotics, treated children were asked to stop using the *salivarius* M18-based product. As there were no dropouts, all the 76 children (38 children in the treated group and 38 in the control, untreated group) attended the follow-up examination performed after 90 days and were included in the statistical analysis.

Study scheme
------------

This randomized, controlled study was conducted in the field of routine clinical practice in the area of Milan (Italy) between March and September 2014, in agreement with the criteria set by the Declaration of Helsinki and the Milan Ethical Board gave the approval for this study. The parents of all the participants in the study were informed of the trial methods and signed the consent and privacy-policy documents giving the authorization to publish the results. As shown in [Figure 1](#f1-ccide-7-107){ref-type="fig"}, 76 of the 100 children analyzed were considered eligible for enrollment and were randomly assigned to be supplemented once a day for 3 months with the test product (treated group; n=38) or not to receive any treatment (control group; n=38). Randomization was carried out using the sealed envelope system. After 90 days, 76 children attended the follow-up examination and were subjected to their second Cariogram test. Every 15 days, during the study, all of the enrolled subjects were in contact with the dentists responsible for the study to report their medical condition and specific study parameters such as probiotic tolerability and dosing compliance, as well as to enable documentation of the occurrence of any side effects possibly linked to the treatment. The subjects were also provided with the possibility of daily access to the physicians responsible for the study.

Tested product
--------------

*Salivarius* M18 (IDA classification: DSM 14865), also named by the manufacturer as BLIS M18 (BLIS Technologies, Dunedin, New Zealand), was formulated as slowly dissolving oral tablets by SIIT (Trezzano S/N, Italy) and notified as nutritional supplement to the Italian Ministry of Health as Carioblis^®^ by Omeopiacenza (Pontenure, Italy), according to the provisions of law 169 of 2004, on July 19, 2013 (notification number 69163). The preparation of Carioblis^®^ used in our research contained no less than 1 billion colony-forming units (CFU)/tablet of strain *salivarius* M18.

Treatment protocol
------------------

Starting from day 0 to 90, one tablet of Carioblis^®^ was administered to each subject every night, just before sleep. The tablet was allowed to slowly dissolve in the oral cavity, without biting or swallowing. Saliva production is typically reduced in the evening hours and this improves the effectiveness of oral colonization. Only for the very first treatment, the administration of the tablet was preceded, approximately 30 minutes before, by the use of a chlorhexidine-based (0.2%) mouthwash. This procedure improves the efficacy of oral colonization by BLIS M18 by creating bacteria-depleted niches in the oral tissues. In order to evaluate the level of subject adherence to the established protocol, the subjects were asked to return any unused product boxes and tablets. Acceptable adherence was considered to be the administration of not less than 95% of the allocated tablets.

Mutans, saliva, and plaque
--------------------------

To evaluate the presence of *S. mutans*, the GC Saliva-Check Mutans test (monoclonal antibody-based) was used. As regards saliva, to evaluate pH and quantity, the GC Saliva-Check Buffer test was used. In order to obtain the samples of saliva for the analysis of mutans streptococci, the saliva secretion rate (mL/min), and buffer capability, paraffin-stimulated whole saliva was collected from all children. The presence of dental plaque was assessed by using the GC Plaque Indicator test. All kits are supplied by GC Europe, Leuven, Belgium.

Study objectives
----------------

The principal objectives for the study were 1) to establish the safety and tolerability profiles of the *salivarius* M18-based product in children at high risk of developing new dental caries and 2) to evaluate in the same children whether any Cariogram modifications occurred after 90 days of treatment with the *salivarius* M18-based product.

Statistical analysis
--------------------

To study the null hypothesis of no effect of treatment on Carioblis^®^ for each clinical variable, and for a global summation, we applied the two-tailed Wilcoxon test for matched pairs with signed ranks. To study the effect of Carioblis^®^ therapy on Cariogram scores, using averaged clinical variables, we used the two-tailed Fisher's exact test. Statistical software JMP^®^ 10 for Mac OS X (SAS Institute Inc., Cary, NC, USA) was used, and the threshold for statistical significance was 95%. To calculate the caries risk of a group of subjects (results are shown in [Table 1](#t1-ccide-7-107){ref-type="table"} and [Figure 2](#f2-ccide-7-107){ref-type="fig"}), we used the average value of any single items of the Cariogram and considered equal to 0 if the decimal values stands between 0.1 and 0.4 and equal to 1 if the decimal values were between 0.5 and 0.9. The Cariogram software used the Java Internet 2004 version.

Results
=======

This randomized and controlled study has been carried out on 76 children at high risk of new dental caries development. Thirty-eight of these subjects were treated for 90 days with Carioblis^®^ (a *S. salivarius* M18-based product) and the others served as controls (untreated group). There was no dropout, therefore all of the children were considered eligible for the statistical analysis. As shown in [Table 2](#t2-ccide-7-107){ref-type="table"}, no statistical differences existed between the two groups in terms of sex and age. Ninety days of treatment with strain M18 produced in the treated group a statistically significant reduction, by more than 30%, in the global Cariogram outcome. No statistical difference was observed in the control group ([Table 3](#t3-ccide-7-107){ref-type="table"}). By analyzing every individual parameter of the Cariogram results in the *salivarius* M18 treated group ([Table 4](#t4-ccide-7-107){ref-type="table"}) one observes that, other than for "caries experience", "related diseases", and "clinical judgment", all of the parameters are improved. Some improvements are probably due to a better control of the aspects of diet (diet content and frequency) or changes in oral hygiene and/or in prophylaxis (fluoride program) and cannot be linked to the treatment, with clear evidence. Others, such as "plaque amount", "mutans streptococci", and "buffer capacity" could be a direct consequence of the treatment because *salivarius* M18 releases bacteriocins able to kill mutans streptococci, and dextranase and urease enzymes, which are capable of counteracting plaque formation and increasing saliva pH, respectively. Noteworthy, "plaque control" and "mutans streptococci" were reduced by approximately 50% and 75%, respectively. By contrast, as shown in [Table 5](#t5-ccide-7-107){ref-type="table"}, the untreated group did not show the same type of improvement and the only statistically significant changes are due to a better control of diet, oral hygiene, and prophylactic approach. The Cariogram software was uniquely implemented to calculate the caries risk of individual subjects. Nevertheless, we have exploited the algorithm of the Cariogram software and used the average value of any single items of the Cariogram to calculate the caries risk of a group of subjects. This nonvalidated procedure allows construction of an image representative of the likely impact that a treatment can have on a group of patients. As shown in [Table 1](#t1-ccide-7-107){ref-type="table"} and [Figure 2](#f2-ccide-7-107){ref-type="fig"}, treatment with the strain M18-based product significantly improves the "chances of avoiding new dental caries", from 20 to 70, reduces the parameter "bacteria", from 29 to 7, and reduces the "susceptibility", from 23 to 9. No relevant variations were evident in the untreated group. Finally, in [Table 6](#t6-ccide-7-107){ref-type="table"}, the M18-based treatment demonstrated a very good safety profile with no treatment-related side effects and no subject dropout. Tolerability was assessed as "good" and "very good" in 35 of the 38 subjects and overlapping results were obtained with regard to compliance.

Discussion
==========

Caries risk assessment is an important tool assisting the dentist in obtaining a better understanding of the dental profile of a patient. The Cariogram software has been clinically proven to be effective in evaluating such a risk.[@b39-ccide-7-107] Cariogram is based on a set of nine pathological and protective factors, in addition to the professional judgment of the expert dentist. Among these factors, the likely most relevant variable in caries risk prediction is "caries experience" and, as a matter of fact, a strong relationship has been shown between caries experience and caries risk profile.[@b40-ccide-7-107],[@b41-ccide-7-107] Apparently, microbial tests, aimed at evaluating the presence of mutans streptococci, do not seem to be equally relevant. This could be because, in the presence of fluoride, along with an appropriate diet in terms of quality and quantity, a high number of mutans streptococci may be tolerated without causing significant harm to the teeth.[@b42-ccide-7-107] Fluoride is not the only potentially protective factor in the presence of an abundance of deleterious streptococci. Within the oral microbiota, populations of mutans streptococci can indeed be balanced by the presence of antagonizing bacteria. Among these, a particularly important role is thought to be played by *S. salivarius*, one of the most prevalent of the commensal oral bacteria. Different strains of *S. salivarius* have been shown capable of counteracting the growth of mutans streptococci[@b8-ccide-7-107] and, of these, the strongest clinical potential has been shown by strain M18.[@b29-ccide-7-107],[@b30-ccide-7-107] On this basis, we decided to test the capability of *salivarius* M18 to modify the Cariogram outcome. According to our results, 90 days treatment with this oral probiotic has increased the chances of avoiding new cavities in children. This outcome is considered attributable to the specific anticariogenic characteristics of strain M18 that, after colonizing the oral mucosa, is able to release bacteriocins, limiting the growth of *S. mutans* and *S. sobrinus*, and the enzymes dextranase and urease, catalyzing the breakdown of dextran (aiding solubilization of plaque) and the hydrolysis of urea (increasing saliva pH). The present study does contain some bias: 1) it is not a blinded study; 2) there is no placebo group; 3) the control group comprises untreated subjects; and 4) the number of enrolled subjects is rather small. Nevertheless, this study represents one of the pioneer attempts to analyze the significance of *salivarius* M18 in dental practice. If these preliminary results can be confirmed with a larger number of subjects and in double-blind clinical conditions, the practical application of strain M18 could be proposed in the future as a new tool in the dentist's armory, along with the already available strategies (eg, anticaries diets, fluoride, and oral hygiene) to be adopted in subjects considered at high risk on the basis of their Cariogram outcome. On the basis of the calculated risk to develop new dental caries, subjects are divided into three groups: low, medium, and high. Depending on these groups, the fundamental aspects of primary prevention are applied to different extents for protocol and rigor: light in those at low risk, moderate in those at intermediate risk, and close and manifold in high-risk individuals. Certainly, in patients defined at high risk, but possibly also in those of intermediate risk, the addition of a protocol incorporating the administration of the *salivarius* M18 could be crucial to addressing and further reducing the risk of tooth-decay receptivity. The caries risk is configured as the predisposition of an individual to be affected by the carious pathology, regardless of the fact of presenting caries at the time of the dental examination. This type of diagnosis precedes then the diagnosis of caries, allowing dentist to intercept the at-risk patient and take the appropriate preventive measures to intercept the development of tooth decay.

The authors thank Dr J Tagg for suggestions and review of the paper.

**Disclosure**

F Di Pierro is the Scientific Director of Velleja Research, the company that developed the finished product tested in this study. The other authors report no other conflicts of interest in this work.

![Scheme of the study.](ccide-7-107Fig1){#f1-ccide-7-107}

![Graphical representation of Cariogram values (%) calculated using the average value of the items listed.\
**Abbreviation:** *Salivarius* M18, *Streptococcus salivarius* M18.](ccide-7-107Fig2){#f2-ccide-7-107}

###### 

Cariogram values (at day 0 and day 90) calculated using the average value of the items listed

  Treatment, time period                                                 Actual chance to avoid new cavities (%)   Diet (%)   Bacteria (%)   Susceptibility (%)   Circumstances (%)
  ---------------------------------------------------------------------- ----------------------------------------- ---------- -------------- -------------------- -------------------
  *Salivarius* M18, day 0                                                20                                        17         29             23                   11
  *Salivarius* M18[\*](#tfn1-ccide-7-107){ref-type="table-fn"}, day 90   70                                        7          7              9                    7
  Untreated, day 0                                                       20                                        17         29             23                   11
  Untreated, day 90                                                      37                                        11         26             16                   10

**Note:**

All values of M18, day 90 are significant (*P*\<0.01) vs treatment M18, day 0.

**Abbreviation:** *Salivarius* M18, *Streptococcus salivarius* M18.

###### 

Characteristics[\*](#tfn3-ccide-7-107){ref-type="table-fn"} of the enrolled children

                    *Salivarius* M18-treated group (n=38)   Untreated group (n=38)
  ----------------- --------------------------------------- ------------------------
  Males, n          25                                      21
  Age° of males     11.2±3.2                                12.1±2.9
  Females, n        13                                      17
  Age° of females   11.5±3.6                                11.8±3.8

**Notes:**

Nonsignificant differences between groups; °age expressed in years ± standard deviation.

**Abbreviation:** *Salivarius* M18, *Streptococcus salivarius* M18.

###### 

Global Cariogram outcome at day 0 and day 90

                                                         *Salivarius* M18-treated group (n=38)                       Untreated group (n=38)
  ------------------------------------------------------ ----------------------------------------------------------- ------------------------
  Day 0[\*\*](#tfn6-ccide-7-107){ref-type="table-fn"}    15.9±2.6 (16)                                               16.3±2.9 (16)
  Day 90[\*\*](#tfn6-ccide-7-107){ref-type="table-fn"}   11.1±2.0 (11)[\*](#tfn5-ccide-7-107){ref-type="table-fn"}   14.4±3.2 (14)
  Δ % vs day 0                                           30.2                                                        11.7

**Notes:**

*P*\<0.01 vs day 0;

data expressed as mean ± standard deviation (median).

**Abbreviation:** *Salivarius* M18, *Streptococcus salivarius* M18.

###### 

Cariogram: outcome of individual parameters in the *salivarius* M18-treated group (n=38)

                        Day 0[\*](#tfn8-ccide-7-107){ref-type="table-fn"}   Day 90[\*](#tfn8-ccide-7-107){ref-type="table-fn"}   *P*
  --------------------- --------------------------------------------------- ---------------------------------------------------- --------
  Caries experience     2.7±0.5 (3)                                         2.7±0.5 (3)                                          ns
  Related diseases      0.0±0.2 (0)                                         0.1±0.2 (0)                                          ns
  Diet, content         1.9±1.0 (2)                                         1.4±0.7 (1)                                          \<0.05
  Diet, frequency       1.4±0.8 (1)                                         1.2±0.5 (1)                                          \<0.05
  Plaque amount         2.0±0.8 (2)                                         1.0±0.6 (1)                                          \<0.01
  Mutans streptococci   2.7±0.5 (3)                                         0.7±0.8 (0)                                          \<0.01
  Fluoride program      2.4±0.7 (2)                                         1.8±0.5 (2)                                          \<0.01
  Saliva secretion      1.7±0.9 (2)                                         1.2±1.1 (1)                                          \<0.05
  Buffer capacity       0.0±0.2 (0)                                         0.0±0.0 (0)                                          \<0.05
  Clinical judgment     1.1±0.4 (1)                                         1.0±0.2 (1)                                          ns

**Note:**

Data expressed as mean ± standard deviation (median).

**Abbreviations:** ns, not significant; *salivarius* M18, *Streptococcus salivarius* M18.

###### 

Cariogram: outcome of individual parameters in the untreated group (n=38)

                        Day 0[\*](#tfn10-ccide-7-107){ref-type="table-fn"}   Day 90[\*](#tfn10-ccide-7-107){ref-type="table-fn"}   *P*
  --------------------- ---------------------------------------------------- ----------------------------------------------------- --------
  Caries experience     2.8±0.5 (3)                                          2.8±0.6 (3)                                           ns
  Related diseases      0.1±0.2 (0)                                          0.2±0.2 (0)                                           ns
  Diet, content         2.0±1.0 (2)                                          1.3±0.4 (1)                                           \<0.01
  Diet, frequency       1.3±0.8 (1)                                          1.1±0.7 (1)                                           \<0.05
  Plaque amount         2.0±0.9 (2)                                          2.1±0.7 (2)                                           ns
  Mutans streptococci   2.6±0.5 (3)                                          2.5±0.6 (3)                                           ns
  Fluoride program      2.3±0.7 (2)                                          1.6±0.7 (1)                                           \<0.01
  Saliva secretion      1.8±0.9 (2)                                          1.4±1.2 (1)                                           \<0.05
  Buffer capacity       0.2±0.2 (0)                                          0.2±0.2 (0)                                           ns
  Clinical judgment     1.2±0.4 (1)                                          1.2±0.1 (1)                                           ns

**Note:**

Data expressed as mean ± standard deviation (median).

**Abbreviation:** ns, not significant.

###### 

Tolerability, compliance, and side effects in children (n=38) treated for 90 days by oral route with *Streptococcus salivarius* M18 as reported by themselves and/or parents and established by dentists responsible for the study

                 Tolerability   Compliance   Side effects
  -------------- -------------- ------------ --------------
  Very good      n=30           n=32         None
  Good           n=5            n=6          None
  Acceptable     n=3            n=0          None
  Unacceptable   n=0            n=0          None
